vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $13.5M, roughly 1.6× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs 7.2%, a 18.0% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 13.6%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 3.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
CUE vs UBFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $13.5M |
| Net Profit | $1.6M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 31.5% |
| Net Margin | 7.2% | 25.2% |
| Revenue YoY | 1292.3% | 13.6% |
| Net Profit YoY | 116.7% | 36.8% |
| EPS (diluted) | $0.05 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $13.5M | ||
| Q3 25 | $2.1M | $14.0M | ||
| Q2 25 | $3.0M | $12.6M | ||
| Q1 25 | $421.0K | $13.7M | ||
| Q4 24 | $1.6M | $11.9M | ||
| Q3 24 | $3.3M | $13.8M | ||
| Q2 24 | $2.7M | $13.0M | ||
| Q1 24 | $1.7M | $12.8M |
| Q4 25 | $1.6M | $3.4M | ||
| Q3 25 | $-7.4M | $4.0M | ||
| Q2 25 | $-8.5M | $2.2M | ||
| Q1 25 | $-12.3M | $2.7M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | $-8.7M | $3.8M | ||
| Q2 24 | $-10.2M | $4.3M | ||
| Q1 24 | $-12.3M | $4.2M |
| Q4 25 | 9.0% | 31.5% | ||
| Q3 25 | -353.4% | 40.3% | ||
| Q2 25 | -292.3% | 24.0% | ||
| Q1 25 | -2921.4% | 27.5% | ||
| Q4 24 | — | 27.5% | ||
| Q3 24 | -264.2% | 37.1% | ||
| Q2 24 | -390.6% | 46.4% | ||
| Q1 24 | -737.8% | 45.9% |
| Q4 25 | 7.2% | 25.2% | ||
| Q3 25 | -346.6% | 28.7% | ||
| Q2 25 | -287.1% | 17.2% | ||
| Q1 25 | -2911.4% | 19.6% | ||
| Q4 24 | — | 20.9% | ||
| Q3 24 | -259.6% | 27.7% | ||
| Q2 24 | -382.7% | 33.0% | ||
| Q1 24 | -719.1% | 32.6% |
| Q4 25 | $0.05 | $0.18 | ||
| Q3 25 | $-0.07 | $0.23 | ||
| Q2 25 | $-0.09 | $0.13 | ||
| Q1 25 | $-0.17 | $0.16 | ||
| Q4 24 | — | $0.14 | ||
| Q3 24 | $-0.17 | $0.22 | ||
| Q2 24 | $-0.20 | $0.25 | ||
| Q1 24 | $-0.25 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $139.7M |
| Total Assets | $42.2M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $264.2M | ||
| Q3 25 | $11.7M | $211.1M | ||
| Q2 25 | $27.5M | $199.5M | ||
| Q1 25 | $13.1M | $198.4M | ||
| Q4 24 | $22.5M | $216.9M | ||
| Q3 24 | $32.4M | $216.8M | ||
| Q2 24 | $30.0M | $166.3M | ||
| Q1 24 | $41.0M | $168.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $139.7M | ||
| Q3 25 | $13.2M | $137.4M | ||
| Q2 25 | $18.2M | $134.3M | ||
| Q1 25 | $6.6M | $132.9M | ||
| Q4 24 | $17.5M | $130.4M | ||
| Q3 24 | $25.4M | $132.9M | ||
| Q2 24 | $21.6M | $127.3M | ||
| Q1 24 | $30.0M | $124.2M |
| Q4 25 | $42.2M | $1.2B | ||
| Q3 25 | $31.6M | $1.2B | ||
| Q2 25 | $40.7M | $1.2B | ||
| Q1 25 | $22.3M | $1.2B | ||
| Q4 24 | $32.2M | $1.2B | ||
| Q3 24 | $44.8M | $1.3B | ||
| Q2 24 | $42.3M | $1.2B | ||
| Q1 24 | $54.0M | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $22.1M |
| Free Cash FlowOCF − Capex | — | $19.8M |
| FCF MarginFCF / Revenue | — | 146.0% |
| Capex IntensityCapex / Revenue | 0.0% | 16.8% |
| Cash ConversionOCF / Net Profit | -0.68× | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $22.1M | ||
| Q3 25 | $-9.0M | $7.0M | ||
| Q2 25 | $-3.4M | $8.7M | ||
| Q1 25 | $-8.2M | $3.0M | ||
| Q4 24 | $-36.3M | $19.6M | ||
| Q3 24 | $-7.5M | $5.4M | ||
| Q2 24 | $-10.0M | $2.3M | ||
| Q1 24 | $-9.8M | $7.4M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $-3.4M | $8.1M | ||
| Q1 25 | $-8.3M | $2.9M | ||
| Q4 24 | $-36.4M | $18.6M | ||
| Q3 24 | $-7.5M | $5.3M | ||
| Q2 24 | $-10.0M | $2.0M | ||
| Q1 24 | $-9.8M | $7.0M |
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | -116.5% | 64.3% | ||
| Q1 25 | -1976.7% | 21.2% | ||
| Q4 24 | -2309.3% | 156.0% | ||
| Q3 24 | -225.7% | 38.1% | ||
| Q2 24 | -376.2% | 15.5% | ||
| Q1 24 | -573.0% | 54.8% |
| Q4 25 | 0.0% | 16.8% | ||
| Q3 25 | 0.0% | 6.0% | ||
| Q2 25 | 0.9% | 4.6% | ||
| Q1 25 | 35.6% | 0.9% | ||
| Q4 24 | 4.2% | 8.7% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.4% | 2.2% | ||
| Q1 24 | 3.2% | 3.6% |
| Q4 25 | -0.68× | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
UBFO
Segment breakdown not available.
